To test the hypothesis that 177 Lu-PSMA is an effective treatment in oHSPC to prolong PFS and postpone the need for androgen deprivation therapy (ADT), we initiated a multicenter randomized clinical trial. This is globally, the first prospective study using 177 Lu-PSMA-I&T in a randomized ...
Single-photon emission CT/CT (SPECT/CT) was performed at 1, 24, 48, 72 and 168 hours after177Lu-PSMA-I&T injection at cycle 1. Tumors >1 cm were categorized based on gallium-68 (68Ga)-PSMA PET mean standardized uptake value (SUVmean): above, at (卤10%), and below liver SUV...
177Lu-PSMA was administered intravenously with 4–8 GBq per treatment cycle (varying 1–6 cycles in total). Any PSA decrease, >30% PSA decline and >50% PSA decline was reached in approximately 75%, 60% and 50%, respectively. Additionally, assessment with 68Ga-PSMA-HBED-CC PET/CT ...
Promising therapeutic results of the prostate-specific membrane antigen (PSMA) ligand have been shown when labelling with lutetium-177 (177Lu). We performed a systematic review and meta-analysis to assess the therapeutic response of 177Lu-PSMA in the treatment of metastatic castration-resistant prosta...
Home Reactions Weekly Article 225-actinium-PSMA/docetaxel/lutetium-177-PSMA-imaging-and-therapy Leucocytopenia, worsening of anaemia and lack of efficacy: 2 case reportsCase report Published: 20 November 2021 Volume 1882, page 14, (2021) Cite this article ...
Lutetium-177 Labelled Anti-PSMA Monoclonal Antibody (Lu-TLX591) Therapy for Metastatic Prostate Cancer: Treatment Toxicity and Outcomes 来自 Springer 喜欢 0 阅读量: 17 作者:H Nguyen,K Hird,J Cardaci,S Smith,NP Lenzo 展开 摘要: Whilst prostate cancer is the fourth most common cancer ...
The physical properties and commercial availability of Lutetium-177 (Lu177) makes it one of the most used radionuclides for radiopharmaceutical therapy (RPT). In this review we aimed at comparing the dosimetry of the most used Lu177-PSMA RPT compounds.Methods:This is a systematic review and ...
The Lu‐177 PSMA‐617 RLT led to a significant PSA response, with 50.6% of patients achieving a >50% decrease in PSA levels. Median overall survival (OS) and progression‐free survival were 13.5 and 8.2?months, respectively. Patients receiving Lu‐177 PSMA‐617 RLT in combination with ...
Purpose: To report our initial clinical experience with a beta-emitting (177)Lutetium-labeled prostate-specific membrane antigen-ligand ((177)Lu-PSMA-I&T) for systemic treatment in metastatic castration-resistant prostate cancer (mCRPC). Material and methods: mCRPC patients who experienced treatment ...
In dit overzichtsartikel wordt de bestaande kennis uit de literatuur met betrekking tot [ 177 Lu]Lu-PSMA therapie, alsmede de ervaringen van de auteurs samengevat. Effectiviteit en oncologische uitkomsten van [ 177 Lu]Lu-PSMA-therapie werden samengevat door verschillende systematische ...